XML 42 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1

Organization and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Schedule of Revenue by Type

The following table represents the Company’s revenue by type for the year ended December 31, 2021, the transition period ended December 31, 2020, and the years ended June 30, 2020 and 2019:

			Year Ended December 31,						Six-month Transition Period Ended December 31,						Years Ended June 30,
(In millions)			2021						2020						2020						2019
Molecular diagnostic revenues:
Hereditary Cancer			$	316.3					$	159.3					$	347.4					$	479.7
Tumor Profiling			120.9						33.9						48.3						43.0
Prenatal			106.8						37.6						76.7						104.9
Pharmacogenomics			93.7						29.8						74.1						112.6
Autoimmune			28.2						18.0						39.1						48.3
Other			0.5						1.0						1.3						0.9
Total molecular diagnostic revenue			666.4						279.6						586.9						789.4
Pharmaceutical and clinical service revenue			24.2						20.2						51.7						61.7
Total revenue			$	690.6					$	299.8					$	638.6					$	851.1

Schedule of Revenue by Geographical Region

In addition, the following tables reconcile revenue by geographical region, either U.S. or rest of world ("RoW"), to total revenue:

			Year Ended December 31,																					Six-month Transition Period Ended December 31,
			2021																					2020
(in millions)			U.S.						RoW						Total									U.S.						RoW						Total
Molecular diagnostic revenues:
Hereditary Cancer			$	271.0					$	45.3					$	316.3								$	140.9					$	18.4					$	159.3
Tumor Profiling			80.4						40.5						120.9									28.2						5.7						33.9
Prenatal			106.2						0.6						106.8									37.4						0.2						37.6
Pharmacogenomics			93.7						—						93.7									29.8						—						29.8
Autoimmune			28.2						—						28.2									18.0						—						18.0
Other			—						0.5						0.5									1.0						—						1.0
Total molecular diagnostic revenue			579.5						86.9						666.4									255.3						24.3						279.6
Pharmaceutical and clinical services revenue			24.2						—						24.2									20.1						0.1						20.2
Total revenue			$	603.7					$	86.9					$	690.6								$	275.4					$	24.4					$	299.8

			Year Ended June 30,
			2020																					2019
(in millions)			U.S.						RoW						Total									U.S.						RoW						Total
Molecular diagnostic revenues:
Hereditary Cancer			$	329.8					$	17.6					$	347.4								$	466.7					$	13.0					$	479.7
Tumor Profiling			39.2						9.1						48.3									34.6						8.4						43.0
Prenatal			76.4						0.3						76.7									104.9						—						104.9
Pharmacogenomics			74.1						—						74.1									112.6						—						112.6
Autoimmune			39.1						—						39.1									48.3						—						48.3
Other			1.2						0.1						1.3									0.5						0.4						0.9
Total molecular diagnostic revenue			559.8						27.1						586.9									767.6						21.8						789.4
Pharmaceutical and clinical services revenue			36.4						15.3						51.7									37.8						23.9						61.7
Total revenue			$	596.2					$	42.4					$	638.6								$	805.4					$	45.7					$	851.1

Reconciliation of Deferred Revenue Balances

A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:

			Year Ended December 31,						Six-month Transition Period Ended December 31,						Years Ended June 30,
(in millions)			2021						2020						2020						2019
Deferred revenue - beginning balance			$	32.7					$	32.8					$	2.2					$	2.6
Revenue recognized			(40.5)						(6.1)						(7.2)						(7.9)
Prepayments			14.0						6.0						37.8						7.5
Divestitures			(1.0)						—						—						—
Deferred revenue - ending balance			$	5.2					$	32.7					$	32.8					$	2.2

Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations

The following is a reconciliation of the denominators of the basic and diluted earnings per share computations:

			Year Ended December 31,						Six-month Transition Period Ended December 31,						Years Ended June 30,
(in millions)			2021						2020						2020						2019
Denominator:
Weighted-average shares outstanding used to compute     basic EPS			78.0						75.0						74.3						73.5
Effect of dilutive stock options			—						—						—						2.5
Weighted-average shares outstanding and dilutive    securities used to compute diluted EPS			78.0						75.0						74.3						76.0

Schedule of Potential Dilutive Common Shares

These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:

			Year Ended December 31,						Six-month Transition Period Ended December 31,						Years Ended June 30,
(in millions)			2021						2020						2020						2019
Anti-dilutive options and RSUs excluded from EPS computation			4.5						6.6						5.5						0.8

Schedule of Cumulative Translation Adjustments Included in Accumulated Other Comprehensive Loss

The following table shows the cumulative translation adjustments included in Accumulated other comprehensive income (loss) (in millions):

Ending balance December 31, 2020			$	(3.1)
Period translation adjustments			(1.8)
Ending balance December 31, 2021			$	(4.9)

X

- References

No definition available.

+ Details

Name:	us-gaap_AccountingPoliciesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph a
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

+ Details

Name:	us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the components of accumulated other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

+ Details

Name:	us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

+ Details

Name:	us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

+ Details

Name:	us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration